ARKG

ARK Genomic Revolution ETF

Actively managed ETF investing in companies involved in CRISPR gene editing, molecular diagnostics, targeted therapeutics, and agricultural biology. High-risk thematic bet on the genomics revolution.

Backtest X-Ray Correlation Risk Map

EquityTER 0.75%Dist.

TER

0.75%

AUM

$2B

CAGR

4.5%

Volatility

36.1%

Sharpe

0.04

Max Drawdown

-79.5%

Data Range

2014-10 → 2026-04

Performance Analysis

Maximum Drawdown History

How far the ETF has fallen from its all-time high at each point. Deeper = more painful.

Current DD-69.6%

Worst DD-79.5%

Worst date2025-03

Rolling Returns

Annualized returns over rolling windows. Shows the range of outcomes depending on when you invested.

Avg return7.4%

Best59.5%

Worst-36.6%

% positive61%

103 periods

Key Facts

ISIN

US00214Q2055

Issuer

ARK Invest

Benchmark

None (actively managed)

Total Expense Ratio (TER)

0.75%

Assets Under Management

$2B approx.

Inception Date

2014-10-31

Domicile

United States

Legal Structure

Open-Ended Fund

Dividend Policy

Distributing (pays dividends)

Replication Method

Physical (Full Replication)

UCITS Status

✗ Not UCITS

Fund Currency

USD

Primary Exchange

NYSE Arca

Number of Holdings

~35

Top 10 Holdings

Top 10 represent 53.8% of the fund.

EXASExact Sciences

9.00%

Healthcare

CRSPCRISPR Therapeutics

7.80%

Healthcare

TWSTTwist Bioscience

6.50%

Healthcare

TEMTempus AI

5.80%

Healthcare

RXRXRecursion Pharma

5.20%

Healthcare

VCYTVeracyte Inc.

4.80%

Healthcare

VERVVerve Therapeutics

4.20%

Healthcare

BEAMBeam Therapeutics

3.80%

Healthcare

FATEFate Therapeutics

3.50%

Healthcare

NTLAIntellia Therapeutics

3.20%

Healthcare

Sector Breakdown

Healthcare

85%

Technology

10%

Industrials

Source: Official issuer data · Last updated: 2026-05-12

Backtest this ETF Official Fund Page

Who Is This ETF For?

✓General portfolio building block for the asset class it covers.

Key Risks to Consider

• Market risk: equity values can drop 30-50% in severe bear markets.

• Non-UCITS: may have unfavorable tax treatment for non-US investors (US estate tax, withholding tax).

Similar ETFs

VT0.07% TER

Vanguard Total World Stock ETF

Total World · Vanguard

VWCE0.19% TER

Vanguard FTSE All-World UCITS ETF (Acc)

Total World (UCITS) · Vanguard

IWDA0.20% TER

iShares Core MSCI World UCITS ETF (Acc)

Developed World (UCITS) · BlackRock

VWRL0.19% TER

Vanguard FTSE All-World UCITS ETF (Dist)

Total World (UCITS Dist) · Vanguard

Continue Your Analysis

Backtest ARKG

Compare ARKG

X-Ray ARKG

Correlation Matrix

Risk vs Return

Check Overlap

Data & Methodology

Metadata sourced from official issuer documentation. Price data from Yahoo Finance (monthly adjusted close, includes reinvested dividends and splits). AUM figures are approximate and updated quarterly.

Data source: Yahoo Finance (adjusted close), ARK Invest (metadata)Last verified: 2026-04-17

Related Guides from FinClaro Chile

What Is an ETF? Complete Guide

Learn the basics of ETFs, how they work, and why they matter

finclaro.cl

ETF Chile vs International Broker

Compare buying ETFs locally vs through international brokers

finclaro.cl

Related ETFs

Similar ETFs

IWDAUCITS

iShares Core MSCI World UCITS ETF (Acc)

TER 0.20%$75B AUM

View Compare

SWDAUCITS

iShares Core MSCI World UCITS ETF (Acc)

TER 0.20%$75B AUM

View Compare

Vanguard Total World Stock ETF

TER 0.07%$48B AUM

View Compare

VEU

Vanguard FTSE All-World ex-US ETF

TER 0.05%$42B AUM

View Compare

Alternative Approaches

SPY

SPDR S&P 500 ETF Trust

TER 0.09%$570B AUM

View Compare

VOO

Vanguard S&P 500 ETF

TER 0.03%$560B AUM

View Compare

IVV

iShares Core S&P 500 ETF

TER 0.03%$560B AUM

View Compare

VTI

Vanguard Total Stock Market ETF

TER 0.03%$435B AUM

View Compare

💬 Frequently Asked Questions

Actively managed ETF investing in companies involved in CRISPR gene editing, molecular diagnostics, targeted therapeutics, and agricultural biology. High-risk thematic bet on the genomics revolution.

ARKG has a total expense ratio (TER) of 0.75%, which means you pay $75 per year for every $10,000 invested.

Yes, ARKG is a distributing ETF that pays dividends to shareholders. The frequency depends on the fund's schedule.

ARKG is a US-domiciled ETF (not UCITS). Non-US investors should consider the US estate tax implications (40% on US assets above $60,000) and the 30% dividend withholding tax (reduced by treaty in some countries).

ARKG uses full physical replication, meaning it holds all (or nearly all) securities in the None (actively managed) index directly.